The case for & against
Bull & Bear analysis
Bullish
Bristol-Myers Squibb Company (NYSE: BMY) is a leading global biopharmaceutical firm dedicated to discovering, developing, and delivering innovative medicines primarily within oncology, immunology, and cardiovascular therapeutic areas. The company is strategically positioned to capitalize on advancements in these critical health sectors, especially as it demonstrates a substantial commitment to building a robust pipeline that aims to address significant unmet needs in various diseases.
Bull says
- ↑Growth portfolio sales rose 17% YoY to $12.3B in Q2 2025.
- ↑Disciplined R&D cuts cycle times by 30% to boost pipeline.
- ↑Six registrational readouts pending provide significant near-term catalysts.
- ↑Dividend yield of 1.32% and $10B debt paydown target enhance fiscal health.
- ↑Early uptake of CoBENFI and Coventry signals strong market reception.
- ↑High earnings yield, solid dividend and positive leverage factors support returns.
Bear says
- ↓Legacy portfolio faces 15%–17% revenue step-down from generics.
- ↓Q2 gross margin fell 280 bps to 70.3% amid mix shifts.
- ↓Inflation Reduction Act and pricing reforms heighten revenue pressure.
- ↓Downward revisions and weak growth factors signal earnings risk.
- ↓Low profitability metrics and waning institutional ownership weigh stock.
- ↓Upcoming trial and launch execution risks may disappoint.
Investment themes with BMY
High Dividend Yield↑ +0.32%
Companies paying above-average dividends
AVGO · JPM · XOM
Pharmaceuticals↓ -1.67%
Drug development driving global healthcare solutions
JNJ · LLY · RPRX
Demographics: Elderly Care↓ -0.26%
Services and products for aging population
UCB.BR · JNJ · AZN
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 04-30-2026bullish
Transcript signals
Bull points
- We believe Coventry has the potential to play a very important role in treating a number of Alzheimer's diseases, safety becomes increasingly important in an elderly population where Coventry is not associated with EPS, sedation, doesn't carry a box warning.
- the AFib study, LibreXia study, has the right sample size and, of course, has a predefined number of events.
- We are recruiting the events as expected, and the events' predefined number is for efficacy and, of course, for safety.
Bear points
- Opdivo revenue decreased 8% to approximately $2.1 billion, with most of this decline coming from the U.S. This was primarily driven by an Opdivo inventory drawdown at the wholesaler level, where inventories are at the low end of the typical range.
Read full transcript analysis ›